IPHYF (Innate Pharma) Net Interest Margin (Bank Only) %


IPHYF Innate Pharma SA IPHYF
40 GF Score
Price $1.65
GF Value $0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

IPHYF
40GF Score
Innate Pharma SA IPHYF
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innate Pharma (IPHYF) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.65 is trading 1000% above its estimated GF Value™ of $0.15. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHYF:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $0.15 vs. price of $1.65 (1000% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
40GF Score

Get the complete analysis for IPHYF

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$0.15
GF Value